FDA approves Abilify drug to treat acute manic and mixed episodes in children

FDA approves Abilify drug to treat acute manic and mixed episodes in children

Abilify, developed by Otsuka jointly with Bristol-Myers Squibb, was approved by the Food and Drug Administration (FDA) for treatment of acute manic and mixed episodes in children aged 10-17 associated with bipolar disorder.

The FDA has given the approval on the basis of four-week-study results. The drug showed effectiveness compared to a placebo.

The drug was first approved on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind in adults.